NBTX — Nanobiotix S.A.

NBTX Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: €32.6 million for FY 2025, a significant increase from a negative €7.2 million in FY 2024, primarily due to a one-time accounting impact from a licensing agreement amendment with Johnson & Johnson (J&J).
• R&D Expenses: Decreased to €23.1 million from €40.5 million in FY 2024, reflecting the transfer of development costs related to the NANORAY-312 study to J&J.
• SG&A Expenses: Slightly decreased to €20.4 million from €20.5 million, indicating continued expense control.
• Net Loss: Reduced to €24 million (€0.50 per share) from €68.1 million (€1.44 per share) in the previous year.
• Cash Position: €52.8 million as of December 31, 2025, up from €49.7 million in 2024, with a cash runway projected into early 2028.

2. Strategic Updates and Business Highlights:

• Collaboration with J&J: Progressing well with the Phase III trial for NBTXR3 in head and neck cancer, with initial results expected in H1 2027. J&J has also initiated a Phase II trial (CONVERGE) for lung cancer.
• Curadigm Platform: Development is ongoing, with four new patent applications filed and positive preclinical data presented. The company is moving towards filing for an IND.
• Partnerships: Over 20 Material Transfer Agreements (MTAs) signed with various pharma and biotech companies to test Curadigm technology.

3. Forward Guidance and Outlook:

• Anticipation of multiple data readouts in 2026, including results from various clinical trials.
• Continued focus on capital-efficient development and maintaining a strong balance sheet.
• Expectation of significant milestone payments from J&J over the next 24-36 months.

4. Bad News, Challenges, or Points of Concern:

• Regulatory Risks: The success of ongoing trials and subsequent approvals remains uncertain, with potential delays in data readouts or trial outcomes.
• Dependence on J&J: The company's future revenue and growth are heavily reliant on the success of J&J's clinical trials and their strategic decisions regarding NBTXR3.
• Market Competition: The oncology market is highly competitive, and NBTX must demonstrate clear advantages over existing therapies to capture market share.

5. Notable Q&A Insights:

• Lung Cancer Data: Initial results from the CONVERGE trial showed promising response rates, but further data will be needed to assess long-term benefits and potential for a Phase III trial.
• J&J's Decision-Making: The decision to file for regulatory approval based on Phase II data will depend on the results and will be made by J&J.
• Curadigm's Development: The company is pursuing both internal and external pathways for the Curadigm platform, with plans to initiate IND filings while also exploring partnerships for further development.

Overall, NBTX is positioned for potential growth with its strategic partnerships and innovative platforms, but it faces inherent risks associated with clinical trial outcomes and market competition.